Hui Feng
冯辉
Hui Feng is a biotech founder and CEO with nearly two decades of big-pharma R&D and management experience, best known as the co-founder of Junshi Biosciences and now the founder and CEO of AllinkBio (安领科生物), an ADC and bispecific antibody company he launched after leaving Junshi. In BlueRun Ventures' framing, he is "one of the leading figures in China's biopharma sector," and his team has been noted for execution speed in advancing the pipeline. AllinkBio raised a $42 million Series A led by BlueRun in late 2024 and extended it to nearly $50 million by December 2025, with Gaorong Capital and BlueRun both re-upping. Feng has described the company's origin as spotting the unmet needs left by PD-1 immunotherapy and aiming to build next-generation drugs with larger clinical value.
AI-generated — may contain errors, please verify.
Coverage
AncorBio in the Hot ADC Race: Mining Differentiated Value in the Innovative Drug 2.0 Era | Gaorong Future
China will inevitably give rise to its own global MNCs.
AllinkBio Closes Nearly $50 Million Series A Extension, BlueRun Ventures Continues to Double Down | BlueRun Family
Accelerating Clinical Development at Full Speed
BlueRun Ventures in Conversation with QUA Biotech, AllinkBio, and Zenitar: Breaking Out of the Red Sea — The "Value" Evolution of China's Innovative Drugs
The Leap from "Imitation and Followership" to "Original Innovation"
Anlink Bio Completes $42 Million Series A Round to Accelerate Global Development of Bispecific Antibodies and ADC Pipeline
Achieving a rapid transition from preclinical to clinical stages.
BlueRun Ventures Leads AllinkBio's $42 Million Series A Round | BlueRun Ventures
Accelerating Global Development of Bispecific Antibodies and ADC Products
